Surfactant therapy in adults with acute lung injury/acute respiratory distress syndrome

Current Opinion in Critical Care

Volumn 12, Issue 1, 2006, Pages 55-60

  Kesecioglu, Jozef ^a   Haitsma, Jack J ^b,c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Acute lung injury; Acute respiratory distress syndrome; Surfactant

Indexed keywords

BERACTANT; CALFACTANT; DIPALMITOYLPHOSPHATIDYLCHOLINE; HL 10; INTERLEUKIN 6; LUSUPULTIDE; PLACEBO; SURFACTANT; SURFACTANT PROTEIN A; SURFACTANT PROTEIN B; SURFACTANT PROTEIN C; SURFACTANT PROTEIN D; UNCLASSIFIED DRUG;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; AEROSOL; ARTIFICIAL VENTILATION; BRONCHOSCOPY; CLINICAL TRIAL; DOSE CALCULATION; DRUG EFFICACY; DRUG INSTILLATION; DRUG SAFETY; HUMAN; LENGTH OF STAY; LUNG LAVAGE; META ANALYSIS; POSITIVE END EXPIRATORY PRESSURE; REVIEW; SURVIVAL; SYSTEMATIC REVIEW; TISSUE OXYGENATION;

EID: 33646111737     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/01.ccx.0000199000.19393.a7     Document Type: Review

References (21)

1. Ware LB, Matthay MA. Acute respiratory distress syndrome. N Engl J Med 2000; 342:1334-1349.
2. Luhr OR, Antonsen K, Karlson M, et al. Am J Respir Crit Care Med 1999; 159:1849-1861.
3. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000; 342:1301-1308.
4. Tsangaris I, Lekka ME, Kitsiouli E, et al. Bronchoalveolar lavage alterations during prolonged ventilation of patients without acute lung injury. Eur Respir J 2003; 21:495-501.
5. Walmrath D, Grimminger F, Pappert D, et al. Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on gas exchange and haemodynamics. Eur Respir J 2002; 19:805-810.
6. Gunther A, Schmidt R, Harodt J, et al. Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on biophysical and biochemical surfactant properties. Eur Respir J 2002; 19:797-804.
7. Spragg RG, Lewis JF, Wurst W, et al. Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant. Am J Respir Crit Care Med 2003; 167:1562-1566.
8. Kesecioglu J, Schultz MJ, Lundberg D, et al. Treatment of acute lung injury (ALI/ARDS) with surfactant. Am J Respir Crit Care Med 2001; 163:A819.
9. Kesecioglu J, Schultz MJ, Maas JJ, et al. Treatment of acute lung injury and ARDS with surfactant is safe. Am J Respir Crit Care Med 2004; 169:A349.
10. Notter RH. Lung surfactants: basic science and clinical applications. In: Lenfant C, editor. Lung biology in health and disease. New York: Marcel Dekker; 2000. pp. 305-308.
11. Rozendaal BAWM van, Golde LMG van, Haagsman HP. Localization and functions of SP-A and SP-D at mucosal surfaces. Pediatr Pathol Mol Med 2001; 20:319-339.
12. Gregory TJ, Steinberg KP, Spragg R, et al. Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1997; 155:1309-1315.
13. Walmrath D, De Vaal JB, Bruining HA, et al. Treatment of ARDS with rSP-C surfactant. Am J Respir Crit Care Med 2000; 161:A379.
14. Anzueto A, Baughman RP, Guntupalli KK, et al. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. N Engl J Med 1996; 334:1417-1421.
15. Spragg RG, Lewis JF, Walmrath HD, et al. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med 2004; 351:884-892. Recent randomized controlled trial which demonstrated an improvement of oxygnation with the instillation of exogenous surfactant in patients with ALI/ARDS compared with conventional treatment. No difference in mortality was observed between the groups. The analysis of the subgroups showed that there was a tendency towards reduced mortality in patients with pneumonia.
16. Willson DF, Thomas NJ, Markovitz BP, et al. Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial. JAMA 2005; 293:470-476. The only randomized controlled trial published so far showing improvement of survival related to exogenous natural surfactant instillation in ALI. The population of this trial consisted of infants, children and adolescents.
17. Gommers D, van't Veen A, Verbrugge SJC, Lachmann B. Comparison of eight different surfactant preparations on improvement of blood gases in lung-lavaged rats. Appl Cardiopulm Pathophysiol 1998; 7:95-102.
18. Ainsworth SB, Beresford MW, Milligan DW, et al. Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25-29 weeks gestation: a randomized trial. Lancet 2000; 355:1387-1392.
19. Lachmann B, Eijking EP, So KL, Gommers D. In vivo evaluation of the inhibitory capacity of human plasma on exogenous surfactant function. Intensive Care Med 1994; 20:6-11.
20. Amato MB, Barbas CS, Medeiros DM, et al. Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med 1998; 338:347-354.
21. Ferguson ND, Kacmarek RM, Chiche JD, et al. Screening of ARDS patients using standardized ventilator settings: influence on enrollment in a clinical trial. Intensive Care Med 2004; 30:1111-1116. This study demonstrates the necessity of a clear and reliable definition of ALI/ARDS in order to include the right patients in the trials. The inclusion of these patients might be one of the reasons why we are seldom able to show the beneficial effects of various treatments in this group of patients.